CY1120521T1 - Παρασκευασμα προμειγματος δεξμεδετομιδινης - Google Patents

Παρασκευασμα προμειγματος δεξμεδετομιδινης

Info

Publication number
CY1120521T1
CY1120521T1 CY20181100462T CY181100462T CY1120521T1 CY 1120521 T1 CY1120521 T1 CY 1120521T1 CY 20181100462 T CY20181100462 T CY 20181100462T CY 181100462 T CY181100462 T CY 181100462T CY 1120521 T1 CY1120521 T1 CY 1120521T1
Authority
CY
Cyprus
Prior art keywords
temxedetomidine
extract
preparation
composition
pharmaceutical compositions
Prior art date
Application number
CY20181100462T
Other languages
English (en)
Inventor
Priyanka Roychowdhury
Robert A. CEDERGREN
Original Assignee
Hospira, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46613447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120521(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira, Inc. filed Critical Hospira, Inc.
Publication of CY1120521T1 publication Critical patent/CY1120521T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Φαρμακευτικές συνθέσεις περιέχουν δεξμεδετομιδίνη ή ένα φαρμακευτικά αποδεκτό άλας αυτής, όπου η σύνθεση παρασκευάζεται ως ένα υγρό για παρεντερική χορήγηση σε ένα υποκείμενο και όπου η σύνθεση είναι τοποθετημένη εντός ενός σφραγισμένου περιέκτη ως ένα πρόμειγμα. Οι φαρμακευτικές συνθέσεις μπορούν να χρησιμοποιούνται στην περιεγχειρητική φροντίδα ενός ασθενούς ή για καταστολή.
CY20181100462T 2012-01-04 2018-05-03 Παρασκευασμα προμειγματος δεξμεδετομιδινης CY1120521T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/343,672 US8242158B1 (en) 2012-01-04 2012-01-04 Dexmedetomidine premix formulation
PCT/US2012/042940 WO2013103378A1 (en) 2012-01-04 2012-06-18 Dexmedetomidine premix formulation

Publications (1)

Publication Number Publication Date
CY1120521T1 true CY1120521T1 (el) 2019-07-10

Family

ID=46613447

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100462T CY1120521T1 (el) 2012-01-04 2018-05-03 Παρασκευασμα προμειγματος δεξμεδετομιδινης

Country Status (35)

Country Link
US (10) US8242158B1 (el)
EP (2) EP3345599A1 (el)
JP (4) JP5892177B2 (el)
KR (1) KR101632103B1 (el)
CN (2) CN103281902A (el)
AR (2) AR089673A1 (el)
AU (1) AU2013201069B1 (el)
BR (1) BR112013008005A8 (el)
CA (1) CA2806706C (el)
CL (1) CL2013000815A1 (el)
CO (1) CO6680698A2 (el)
CY (1) CY1120521T1 (el)
DK (1) DK2648520T3 (el)
EC (1) ECSP13012569A (el)
ES (1) ES2671749T3 (el)
GT (1) GT201300055A (el)
HK (1) HK1249429A1 (el)
HR (1) HRP20180838T1 (el)
HU (1) HUE038128T2 (el)
IL (1) IL224867B (el)
LT (1) LT2648520T (el)
MX (1) MX2013003629A (el)
MY (2) MY188598A (el)
PE (2) PE20160681A1 (el)
PL (1) PL2648520T3 (el)
PT (1) PT2648520T (el)
RS (1) RS57346B1 (el)
SA (2) SA115360458B1 (el)
SG (1) SG191706A1 (el)
SI (1) SI2648520T1 (el)
TR (1) TR201809123T4 (el)
TW (2) TWI574688B (el)
UY (1) UY34562A (el)
WO (1) WO2013103378A1 (el)
ZA (1) ZA201301649B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
BR112016006848A2 (pt) * 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
US20150098983A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions
MX2016007902A (es) * 2013-12-18 2016-10-28 Gnt Llc Composiciones y metodos para el tratamiento del glaucoma.
FI127534B (en) * 2014-11-10 2018-08-31 Vetcare Oy Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions
CN106038538A (zh) * 2015-04-17 2016-10-26 江苏恒瑞医药股份有限公司 一种右美托咪定的预混合制剂
CN105168122B (zh) * 2015-09-24 2018-11-27 辰欣药业股份有限公司 一种盐酸右美托咪定注射液及其制备工艺
US20170128421A1 (en) * 2015-11-11 2017-05-11 Siva Prasad Reddy Sura Premix formulation for parenteral use and packaging thereof
US10632043B2 (en) * 2015-11-11 2020-04-28 Aurobindo Pharma Ltd Premix formulation for parenteral use and packaging thereof
US9717796B1 (en) * 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
CN107412152B (zh) * 2016-05-24 2020-12-04 海南合瑞制药股份有限公司 一种盐酸右美托咪定注射液组合物
EP3560495B1 (en) * 2016-12-26 2021-07-28 Hisamitsu Pharmaceutical Co., Inc. Microneedle device
CN110337290A (zh) 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
CN107028880A (zh) * 2017-06-09 2017-08-11 安徽赛诺制药有限公司 一种盐酸右美托咪定注射液的生产工艺
US20190262314A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
CN108956809B (zh) * 2018-06-04 2021-03-23 四川科伦药物研究院有限公司 一种检测1-(1-氯乙基)-2,3-二甲苯有关物质的方法
WO2020006119A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CN114983979A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN109081811A (zh) * 2018-09-19 2018-12-25 南京正大天晴制药有限公司 盐酸右美托咪定的有关物质及其制备方法
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
CN116615243A (zh) * 2020-10-08 2023-08-18 比奥克斯塞尔医疗股份有限公司 使用右美托咪啶盐酸盐治疗躁郁症和精神病
EP4085891A1 (en) 2021-05-05 2022-11-09 B. Braun Melsungen AG Dexmedetomidine-solution in a low-density polyethylene container
CN113041242A (zh) * 2021-05-18 2021-06-29 上海交通大学医学院附属仁济医院 右美托咪定在促进肝脏再生中的应用
CN113116815A (zh) * 2021-06-07 2021-07-16 辰欣药业股份有限公司 一种盐酸右美托咪定注射液的制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPS6058890A (ja) 1983-09-13 1985-04-05 Mizusawa Ind Chem Ltd 感熱記録紙用填剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
DE69519300T2 (de) * 1994-08-08 2001-05-31 Debiopharm Sa Stabiles arzneimittel enthaltend oxaliplatin
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
EP1121933A1 (en) 2000-02-02 2001-08-08 Pfizer Products Inc. Premixed alatrofloxacin injectable compositions
US6310094B1 (en) 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
ATE386512T1 (de) 2001-03-29 2008-03-15 Baxter Int Vorgemischte amiodaron-haltige parenterale lösung und deren herstellungsverfahren
US6806291B1 (en) * 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
BRPI0604377A (pt) 2006-10-27 2008-06-24 Cristalia Prod Quimicos Farm microemulsão óleo/água de propofol estável e pronta-para-uso
US20080308444A1 (en) * 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8100890B2 (en) * 2008-10-15 2012-01-24 Bioquiddity, Inc. Special purpose fluid dispenser with pre-filled reservoir
JP5536661B2 (ja) 2008-10-30 2014-07-02 国立大学法人 岡山大学 局所麻酔用組成物
MX2011011950A (es) 2009-05-15 2012-02-21 Recro Pharma Inc Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
US8410140B2 (en) * 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
EP2459170A2 (en) 2009-07-31 2012-06-06 Astron Research Limited A stable composition of ready-to-use gemcitabine injection
WO2011075621A1 (en) 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Also Published As

Publication number Publication date
US20160175285A1 (en) 2016-06-23
AR117001A2 (es) 2021-06-30
WO2013103378A1 (en) 2013-07-11
DK2648520T3 (en) 2018-06-18
TR201809123T4 (tr) 2018-07-23
US9616049B2 (en) 2017-04-11
SI2648520T1 (en) 2018-08-31
CA2806706A1 (en) 2013-07-04
GT201300055A (es) 2014-08-26
US20180289673A1 (en) 2018-10-11
US9320712B2 (en) 2016-04-26
TWI593409B (zh) 2017-08-01
SA113340176B1 (ar) 2015-07-26
US20180289674A1 (en) 2018-10-11
MY161022A (en) 2017-03-31
AU2013201069B1 (en) 2013-08-15
US10016396B2 (en) 2018-07-10
KR101632103B1 (ko) 2016-06-20
HK1249429A1 (zh) 2018-11-02
PL2648520T3 (pl) 2018-08-31
BR112013008005A8 (pt) 2018-01-09
NZ607555A (en) 2015-08-28
JP2014088433A (ja) 2014-05-15
ECSP13012569A (es) 2015-04-30
BR112013008005A2 (pt) 2016-06-14
ES2671749T3 (es) 2018-06-08
HRP20180838T1 (hr) 2018-06-29
IL224867A0 (en) 2013-06-27
EP2648520B1 (en) 2018-04-11
TW201630603A (zh) 2016-09-01
UY34562A (es) 2014-07-31
JP5990832B2 (ja) 2016-09-14
MX2013003629A (es) 2013-11-05
CA2806706C (en) 2015-07-14
CN107802624A (zh) 2018-03-16
US8436033B1 (en) 2013-05-07
TWI574688B (zh) 2017-03-21
RS57346B1 (sr) 2018-08-31
ZA201301649B (en) 2014-08-27
US8648106B2 (en) 2014-02-11
AR089673A1 (es) 2014-09-10
US20140155446A1 (en) 2014-06-05
US20170165235A1 (en) 2017-06-15
JP2015110639A (ja) 2015-06-18
PE20160681A1 (es) 2016-07-28
CN103281902A (zh) 2013-09-04
PT2648520T (pt) 2018-06-06
JP2014058577A (ja) 2014-04-03
JP5892177B2 (ja) 2016-03-23
US8338470B1 (en) 2012-12-25
JP2014508746A (ja) 2014-04-10
JP5927680B2 (ja) 2016-06-01
KR20140096238A (ko) 2014-08-05
SG191706A1 (en) 2013-08-30
EP2648520A1 (en) 2013-10-16
HUE038128T2 (hu) 2018-09-28
PE20131166A1 (es) 2013-10-05
EP2648520A4 (en) 2014-05-21
EP3345599A1 (en) 2018-07-11
MY188598A (en) 2021-12-22
CL2013000815A1 (es) 2013-09-06
CO6680698A2 (es) 2013-05-31
US8455527B1 (en) 2013-06-04
LT2648520T (lt) 2018-07-10
TW201332546A (zh) 2013-08-16
SA115360458B1 (ar) 2016-01-27
US20130237576A1 (en) 2013-09-12
IL224867B (en) 2018-01-31
US8242158B1 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
CY1120521T1 (el) Παρασκευασμα προμειγματος δεξμεδετομιδινης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
NI201500167A (es) Compuestos químicos
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201591195A1 (ru) Новые хинолоновые производные
CR20180316A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
DOP2015000170A (es) Compuestos químicos
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201501163A1 (ru) Модуляторы рецептора cxcr7
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
MX368635B (es) Compuestos tricíclicos de piperidina.
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EA201500313A1 (ru) Стабилизированная аморфная форма агомелатина, способ ее изготовления и фармацевтические композиции, ее содержащие
EA201590732A1 (ru) Диспергируемая таблетка
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант